Clinical Trials Logo

Depressive Episode clinical trials

View clinical trials related to Depressive Episode.

Filter by:

NCT ID: NCT05701345 Not yet recruiting - Clinical trials for Major Depressive Disorder

Study of Virtual Reality-based Medical Device for Patients With Depressive Disorder

Start date: January 30, 2023
Phase: Phase 3
Study type: Interventional

This study apply a wearable visual device (HMD)-VR-based software medical device for patients with depressive disorder for 8 weeks. The investigator would like to confirm evaluate the safety and efficacy of the wearable visual device(HMD)-VR-based software medical device effect of improving depressive disorder in patients.

NCT ID: NCT05691647 Not yet recruiting - Depressive Episode Clinical Trials

Chronotherapy for Depressive Episodes

Start date: January 2023
Phase: N/A
Study type: Interventional

Evidence-based treatments for depression, such as antidepressive medication, usually have a latency of 4 to 6 weeks before they achieve a therapeutic effect. Chronotherapy is a group of non-pharmacological interventions that presumably act on the circadian system to achieve a rapid-onset clinical effect and better long-term effects and has been shown efficient to improve depressive symptoms. Interventions include sleep deprivation, sleep-phase advancement and stabilization, and light therapy. There are few studies testing the effectiveness of combining these three chronotherapeutic techniques in the initial phase of treatment of depression in a secondary mental health care outpatient clinic. The investigators aim to test the effects and safety of chronotherapy in addition to TAU compared to TAU alone, with the primary outcome being self-reported depressive symptoms at 1 week following randomization. The study is a randomized controlled trial with 76 patients with a depressive episode who initiate outpatient treatment at Nidaros DPS, St. Olavs University Hospital. Participants will be allocated 1:1 to either chronotherapy + treatment as usual (TAU) or to TAU alone.

NCT ID: NCT05686408 Not yet recruiting - Depression Clinical Trials

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

UPLIFT
Start date: February 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).

NCT ID: NCT05683028 Recruiting - Depressive Episode Clinical Trials

RCT for Electroconvulsive Treatment Followed by Cognitive Control Training

ECT-CCT
Start date: May 1, 2020
Phase: N/A
Study type: Interventional

Major depressive disorder (MDD) is worldwide one of the most prevalent and disabling mental health conditions. Electroconvulsive therapy (ECT) is a safe and effective treatment even though 6-month relapse rates are high. Cognitive side effects of ECT, such as reduced cognitive control, might trigger mechanisms that increase relapse in patients. As such, cognitive control training (CCT) holds promise as a non-pharmacological strategy to improve long-term effects of ECT (i.e., increase remission, and reduce depression relapse).

NCT ID: NCT05678907 Not yet recruiting - Depressive Episode Clinical Trials

Predictive Value of the DD4 Questionnaire on Depressive Relapse After Hospitalization.

PRADESH
Start date: January 2, 2023
Phase:
Study type: Observational

This is a prospective, longitudinal, single-center observational study of data from the medical records of patients hospitalized after a characterized depressive episode and reviewed three months after hospital discharge, as part of a normally scheduled evaluation.

NCT ID: NCT05654948 Not yet recruiting - Depressive Episode Clinical Trials

Characterisation of Fundamental Decision Making in People Suffering From a Characterised Depressive Episode

MINDDE
Start date: February 2023
Phase:
Study type: Observational

The investigators will include patients suffering from Major Depressive Disorder (MDD), in episode. The patients will undertake neuropsychological tasks evaluating executive function and clinical assessment related to depressive symptoms, anxiety, transdiagnostic symptoms and psychological skills.

NCT ID: NCT05641623 Recruiting - Depression Clinical Trials

OSU6162 as add-on in SSRI/SNRI-resistant Depression

ODEN
Start date: April 21, 2022
Phase: Phase 2
Study type: Interventional

This is a randomised, placebo-controlled, parallel-group trial comparing OSU6162 at flexible dosage with placebo as add-on to treatment with an SSRI/SNRI in patients with depression that have not responded to treatment with an SSRI/SNRI per se for at least 6 weeks. The study will last for 6 weeks, after which those not having responded will leave the trial and those having responded will be offered to continue treatment without unblinding for another 4 weeks. While assessment of the efficacy and safety of OSU6162 is the main objective of this study, possible differences between the two treatment groups with respect to a number of biomarkers in serum will also be explored.

NCT ID: NCT05547711 Not yet recruiting - Depression Clinical Trials

Prediction and Validation of Unipolar Depression With Psychosocial-somatic Markers in a Naturalistic Cohort Recruited in an Outpatient Setting

POKAL-PSY
Start date: October 15, 2022
Phase: N/A
Study type: Interventional

The POKAL-PSY project is a study that monitors participants for five years. The goal of the study is to identify distinguishable subtypes of depression on the basis of biomarkers and to gain insight into their prognostic significance.

NCT ID: NCT05462652 Recruiting - Depression Clinical Trials

Self-guided Treatment for Adolescents Navigating Depression

Start date: July 28, 2022
Phase: N/A
Study type: Interventional

The goal of this study is to test whether an investigational mobile app can be a helpful treatment option for adolescents with symptoms of depression. Adolescents aged 13 to 21 with depression symptoms can be part of this study if eligible. Eligible participants will be randomly assigned to one of two groups: one group will receive the mobile app intervention in addition to their usual care and the other group will simply continue their usual care for symptoms of depression. Both groups will have 5 weeks to use a study app.

NCT ID: NCT05461599 Enrolling by invitation - Depression Clinical Trials

Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology

Start date: August 25, 2022
Phase: N/A
Study type: Interventional

The primary aim of this pilot study is to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for symptoms of depression among adolescents being treated in specialty medical care settings at Children's Hospital of Los Angeles (CHLA).